|
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f21c6f66-8b2f-4b6c-a13d-fd8e9822d37b
Distribution Contract for Test Kits in
ViraxClear has received initial orders for trials and market testing of their Test Kits for the Chilean market and manufacturing is expected to commence over the next 60 days. The LOI provides for a 60-day exclusivity period during which ViraxClear and Biosonda intend to sign a definitive agreement with a total contract value of up to
Biosonda is a biotechnology company founded in
The Biosonda commercial department is made up of a sales force, with a high degree of specialization and extensive experience in the market made up of experts in molecular biology and immunology. They offer a technical service laboratory for equipment maintenance, repair and training, a personalized after-sales service, and a commercial-logistics team that manages the tasks of quotation, import, logistics, inventory, orders and dispatch to provide an optimum service.
ISP Approval
The Chilean government require medical testing devices to receive ISP Approval before they can be sold in
Established in 2006, Innovita is a Chinese high-tech enterprise specialized in R&D, manufacturing, marketing and after-sales service of In-vitro diagnostic tests. The CE and NMPA (formerly known as CFDA) approved Innovita serology tests have performed particularly well during preliminary clinical tests carried out by the
Vazyme, which is a highly reputable producer of enzymes and antibodies with products covering clinical diagnosis, molecular diagnostics, high-throughput sequencing and life science research, as well as RNA sequencing, enabling customers and reagent manufacturers to get enzymes with higher resistance. Vazyme owns a dedicated 8000 m2 R&D site and have established the
The Test Kits are intended for the qualitative detection of IgG and IgM antibodies against 2019 Novel Coronavirus, produced by the immune system after virus infection. IgM is the earliest antibody that appears upon the first immune response, with detection indicating an early stage infection. IgG is produced later and lasts a long time in the body, indicating a prior infection. The combination of the two markers offers an insight into what stage the virus has reached.
About ViraxClear
ViraxClear focuses on commercializing novel products that address significant healthcare needs with a specific target on the novel coronavirus (COVID-19). The company’s main focus is marketing its ViraxClear Rapid IgM-IgG Combined Antibody Test. The ViraxClear Rapid IgM-IgG Combined Antibody Test for COVID-19 is a lateral flow immunoassay used to qualitatively detect both early and late marker IgG/IgM antibodies.
http://www.viraxclear.com
info@viraxclear.com
About Global Care
http://www.globalcarecapital.com
Company Contact:
asomjen@globalcarecapital.com
Neither the CSE nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com
Source:
2020 GlobeNewswire, Inc., source